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The most common causes of urinary tract infections (UTIs) are Gram-negative pathogens such as Escherichia coli; however,
Gram-positive organisms, including Streptococcus agalactiae, or group B streptococcus (GBS), also cause UTI. In GBS infection,
UTI progresses to cystitis once the bacteria colonize the bladder, but the host responses triggered in the bladder immediately
following infection are largely unknown. Here, we used genome-wide expression profiling to map the bladder transcriptome of
GBS UTI in mice infected transurethrally with uropathogenic GBS that was cultured from a 35-year-old women with cystitis.
RNA from bladders was applied to Affymetrix Gene-1.0STmicroarrays; quantitative reverse transcriptase PCR (qRT-PCR) was
used to analyze selected gene responses identified in array data sets. A surprisingly small significant-gene list of 172 genes was
identified at 24 h; this compared to 2,507 genes identified in a side-by-side comparison with uropathogenic E. coli (UPEC). No
genes exhibited significantly altered expression at 2 h in GBS-infected mice according to arrays despite high bladder bacterial
loads at this early time point. The absence of a marked early host response to GBS juxtaposed with broad-based bladder re-
sponses activated by UPEC at 2 h. Bioinformatics analyses, including integrative system-level network mapping, revealed multi-
ple activated biological pathways in the GBS bladder transcriptome that regulate leukocyte activation, inflammation, apoptosis,
and cytokine-chemokine biosynthesis. These findings define a novel, minimalistic type of bladder host response triggered by
GBS UTI, which comprises collective antimicrobial pathways that differ dramatically from those activated by UPEC. Overall,
this study emphasizes the unique nature of bladder immune activationmechanisms triggered by distinct uropathogens.
Urinary tract infections (UTIs) are among the most commoninfectious diseases of humans, with up to 40% of healthy
adult women experiencing at least one UTI episode in their life-
time (24). Gram-negative bacteria, most notably, uropathogenic
Escherichia coli (UPEC), are the leading cause of UTIs. These or-
ganisms express a range of virulence factors that provoke inflam-
mation in the bladder as part of the early steps ofUTI pathogenesis
(34, 47, 69, 91). Rapid host inflammatory cascades are initiated in
the bladder following UPEC infection, and these encompass in-
terleukins (ILs) (8, 51, 52, 68), tumor necrosis factor (TNF), nitric
oxide (16), and CXC chemokine receptor 2 (50), among other
host factors (7, 65–67). Notably, UPEC may also suppress innate
immune activation as a virulence strategy (7, 41, 75), and roles for
immune suppressive and regulatory elements, including Th17
cells and IL-10, were recently shown in the bladder response lead-
ing to UPEC UTI pathogenesis (13, 70).
Gram-positive pathogens are less frequently associated with
UTIs than organisms such as E. coli but are nonetheless common
causes ofUTI (63). Streptococcus agalactiae, also known as groupB
streptococcus (GBS), has emerged in the past 10 years as an im-
portant Gram-positive uropathogen. GBS is generally associated
with maternal cervicovaginal colonization and disease in new-
borns and older persons with chronicmedical illness (3, 15); how-
ever, GBS also causes acute and subacute UTI. GBS UTIs include
asymptomatic bacteriuria (ABU), cystitis, pyelonephritis, and
urosepsis, which, clinically, are indistinguishable from UTIs
caused by other uropathogens (46). Urinary GBS is cultured from
1% to 2% of all cases of clinically suspected UTI (84), and GBS
UTI complicates up to 7% of pregnancies andmay account for up
to 10%of pyelonephritis during pregnancy (46, 54). GBSUTImay
also contribute to chorioamnionitis (1) and premature onset of
labor (44) and has been associated with an increased risk of verti-
cal transmission of the bacteria to infants (55, 90). While the in-
cidence of GBS neonatal disease has decreased in the past decade,
diseases such as UTI have increased in adults during this period
(15).
In terms of the mechanisms of virulence and disease underly-
ing GBS UTI, high rates of ABU among elderly adults (15, 19, 46)
prompted a recent survey of the GBS serotypes that cause UTI,
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since distinct serotypes of GBS, most notably types III, Ia, and V,
are associated with invasive disease in neonates and adults (84). In
that study, a wide spectrumof serotypes were shown to causeUTI,
with a disproportionately high distribution of serotype III isolates
associated with acute disease. The pathogenesis of GBSUTI, how-
ever, and the immune responses that are initiated in the bladder
during infection are largely unknown. GBS UTI triggers high lev-
els of IL-1 in the bladder (83) and also upregulates macrophage
inflammatory protein-1 (MIP-1), MIP-1, IL-9, and IL-10
(35). These findings suggest that, despite GBSUTI being clinically
indistinguishable from UTI caused by other pathogens, divergent
mechanisms of pathogenesis are associated with cystitis caused
by GBS.
The lack of knowledge on the pathogenesis of acute GBS UTI
prompted us to map the bladder transcriptome of GBS cystitis in
mice to define the host pathogen interactions that occur immedi-
ately after infection. Comparing the bladder defense pathways ini-
tiated by GBS with those triggered by UPEC on a genome-wide
scale revealed a unique bladder response triggered byGBSwhich is
both more limited in scope and slower to develop than that seen
with the prototypic Gram-negative uropathogen. This report pro-
vides new insight into defense strategies in the host bladder and
uncovers a surprisingly minimal local transcriptional program in
acuteGBSUTI that develops in a focused, pathogen-specificman-
ner.(This study was presented in part at the American Society for
Microbiology Annual General Meeting, 21 to 24 May 2011, New
Orleans, LA [76a]).
MATERIALS AND METHODS
Bacteria. The uropathogenic GBS used in this study was cultured from
clean-catch voided urine of a 35-year-old nondiabetic woman with no
identified risk factors who presented to the University of Alabama at Bir-
mingham (UAB) Hospital with symptoms that were consistent with un-
complicated cystitis, including dysuria, single-organism bacteriuria
( 100,000 CFU/ml), and leukocyte esterase and pyuria (10 white
blood cells [WBC]/l; nonspun), noted on urinalysis. GBS was grown at
37°C on Todd-Hewitt (TH) agar or in Todd-Hewitt broth (THB). Cap-
sular serotyping, which identified this isolate as serotype III, was per-
formed as described elsewhere (84). Use of the GBS cultured from the
patient in this study was enacted according to the principles of the Hel-
sinki Declaration with approval from the Institutional Review Board
(IRB) of UAB (X070722011) and theHuman Ethics Committee (HEC) of
Griffith University (MSC/11/10/HREC). The UAB IRB and the Griffith
University HEC waived the need for specific informed consent. In some
comparative assays, we used the prototype UPEC CFT073 strain (ATCC
700928), which was originally cultured from a patient with pyelonephritis
(43). This strain has been used inmultiple pathogenesis studies inmice, as
previously described (32, 38, 82, 92).
Analysis of GBS adherence to bladder uroepithelium. Initially, we
sought to determine whether the uropathogenic serotype III GBS isolate
in this study was capable of binding to bladder cells in vitro. For this, we
performed binding assays using T24 and 5637 human bladder uroepithe-
lial cells (ATCC; HTB-4, HTB-9). Thirty thousand bladder cells were
grown in poly-D-lysine-coated multiwell chamber slides (BD BioCoat) as
previously described (83). Fluorescein isothiocyanate (FITC)-stained
GBS (0.25 mg ml1 in phosphate-buffered saline [PBS], 15 min, 37°C)
were added (multiplicity of infection [MOI], 100 CFU cell1), and after 2
h, monolayers were rinsed with PBS and fixed for 45 min with 3% para-
formaldehyde and F-actin was labeled with phalloidin Alexa Fluor 594
(Molecular Probes) to colocalize GBS with host cell surfaces. DNA was
counterstained with the nuclear dye Hoechst 33258. Cells were visualized
with a Leica TCS SP2 confocal microscope. We also performed quantita-
tive measurements of GBS binding to 5637 bladder uroepithelial cells by
the use of antibiotic protection assays at 30 min (initial binding), 2 h
(initial binding and invasion), and 24 h (intracellular survival), as de-
scribed elsewhere (80). Briefly, 5 104 to 8 104 cells were seeded into
wells of a 24-well tissue culture-treated plate (Nunc), grown for 24 h at
37°C in 5% CO2, and challenged at a multiplicity of infection of 10 bac-
teria per uroepithelial cell. After 30 min or 2 h, monolayers were rinsed
with PBS (five times) and either themonolayers were processed for colony
counts to determine numbers of adherent GBS or fresh mediumwith 100
U/ml penicillin, streptomycin, and gentamicin was added for subsequent
processing at 24 h to measure intracellular GBS (78, 81). For some assays,
supernatants from quadruplicate cultures were collected at 30 min, 2 h,
and 24 h for analysis using an 8-target multiplex protein assay (Bio-Rad
Laboratories, Australia) to assess the role of the uroepithelial cells in host
responses to GBS.
Murinemodel ofGBS cystitis.FemaleC57BL/6mice (8 to 10weeks of
age) were purchased from the Animal Resources Center (Australia) and
Jackson Laboratories (United States). Urine was collected 24 h prior to
challenge and examined microscopically and by culture to exclude mice
with a preexisting condition as described elsewhere (85). Mice were anes-
thetized by isoflurane, and the periurethral area was sterilized with 10%
povidone–iodine. Mice were catheterized using a sterile catheter, and 40
l of PBS containing the challenge inoculumwas instilled into the bladder
in a transurethral manner. Control mice received PBS only. For compar-
isons with UPEC, another group of mice received an equivalent dose of
strain CFT073 (based on equal cell numbers) that was grown at 37°C in
lysogeny broth as previously described (13). Urine was collected at 22 to
24 h for colony counts, after which mice were euthanized and bladders
removed and homogenized for counts or processed for microscopy to
visualize GBS binding to the uroepithelial surface. Escalating-dose exper-
iments were used to determine the 90% infectious dose (ID90) of the GBS
isolate based on the methods of Reed andMuench (61). A challenge dose
of approximately 3 109 CFU was used in most assays unless otherwise
indicated. In some experiments, bladders were collected from mice 30
min after challenge and were sectioned and washed in PBS (five washes of
5 min each wash, in 1 ml, with rotation) and then processed as normal to
determine the numbers of initially adherent GBS in the bladder. Immu-
nohistochemistry (IHC) analysis was also performed on duplicate blad-
ders for histological assessment of local cellular infiltrates. This processing
was based on standard IHC methods performed with rat anti-mouse
Ly-6g (GR-1) (eBiosciences, San Diego, CA) and goat anti-rat IgG-FITC
conjugate (Southern Biotech, Birmingham, AL). To visualize the distri-
bution of FITC-stained GBS on the bladder uroepithelium, fluorescence
dissection stereomicroscopy was performed using an Olympus SZX16
microscope fitted with a charge-coupled-device (CCD) DP72 camera.
Additional bright-field and epifluorescence microscopy was performed
using an AxioImager M2 microscope fitted with AxioCam MRm Rev. 3
and MRc 5 cameras (Carl Zeiss, Australia). All animal studies were
performed with approval from and in accordance with the ethical
standards of the Animal Ethics Committee of Griffith University
(MSC/14/08/AEC) and the Institutional Animal Care and Use Com-
mittee of UAB (080708186).
Urine growth assays. To determine whether GBS growth in urine
could affect the colonization dynamics of the organisms in the bladder, we
undertook in vitro urine growth assays. Human urine was collected from
six healthy adult volunteers who had not had UTI or undergone any
antibiotic treatment in the 2 weeks prior. Equal volumes of urine were
pooled, filter sterilized (0.45-m-pore-size filters), and stored at 4°C until
use (within 48 h). Growth assays were also performed using mouse urine.
Duplicate 200-l aliquotswere inoculatedwith approximately 103CFUof
GBS and grown in 96-well microtiter plates at 37°C with shaking (200
rpm), and the optical density at 600 nm (OD600) was recorded between 0
and 72 h. The growth experiments were repeated three times, and data
from one representative experiment are shown. Ethics approval for use of
human volunteer subjects was granted by Griffith University (Human
Research Ethics Committee approval MSC/11/10/HREC).
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Electron microscopy. For scanning electron microscopy (SEM),
whole bladders were collected from euthanizedmice at 2 h after transure-
thral challenge and immediately fixed in 3% glutaraldehyde–0.1 M caco-
dylate buffer (pH 7.4) and stored at 4°C until processing. After being
washed in fresh buffer, bladders were pinned onto wax sheets to prevent
curling, postfixed in 1% osmium tetroxide, and then dehydrated through
a graded ethanol series and critical point dried. Samples weremounted on
SEM stubs and sputter coated with platinum for viewing using a JEOL
6300F SEM operated at 8 kV.
RNA isolation and microarrays. Total RNA was isolated from GBS-
infected, UPEC-infected, and PBS (control) bladders at 2 h and 24 h after
challenge using group sizes of five mice per treatment group per time
point. Total RNA was isolated using TRIzol reagent (Gibco) according to
the manufacturer’s instructions, treated with RNase-free DNase, and an-
alyzed using a Bioanalyzer 2100 instrument (Agilent). RNA that passed
Bioanalyzer analysis was quantified, and 100 ng was amplified into cDNA
using SuperScript III reverse transcriptase (Invitrogen) with randomhex-
amers tagged with a T7 promoter sequence. Microarray analyses were
carried out in quintuplicate for each group and time point using one array
per mouse (each array representing one single bladder). This approach
provided a high degree of statistical power based on nonpooled samples to
incorporate variances between mice within each treatment group. We
regarded the use of five biological replicates (mice) in each treatment
group and time point preferable to technical replicate experiments, which
were not performed.
qRT-PCR. To interrogate array data sets, quantitative reverse trans-
criptase PCR (qRT-PCR) was carried out for selected genes (listed in
Table 1) that were identified as differentially regulated or unchanged fol-
lowing the treatment according to array analysis. Amplification of cDNA
(500 ng RNA amplified) was performed using a GeneAmp 7700 system
(Applied Biosystems). Target genes were amplified using thermal cycling
conditions previously described (13, 83). Glyceraldehyde-3-phosphate
TABLE 1 qRT-PCR data for selected genes identified as significantly changed or unchanged in expression at 2 and 24 h postinfection in bladder
during GBS cystitis according to microarrays
Target genea Time (h)
Mean CT SEM (n 5)
	CT Fold change P
bControl Infected
CXCL10 2 34.111 1.29 33.351 0.53 0.75 1.411 0.110
24 35.208 3.14 28.019 6.82 7.189 30.75 0.001
iNOS 2 36.73 1.25 36.75 2.02 0.02 1.082 0.817
24 35.73 0.44 32.26 2.81 3.47 11.92 0.001
CCL5 2 28.37 1.40 28.425 1.02 0.055 1.4 0.153
24 29.192 1.15 28.015 1.21 1.177 2.525 0.003
CXCL5 2 35.34 0.87 35.21 2.45 0.13 1.13 0.717
24 35.64 0.56 33.73 1.80 1.91 4.96 0.001
CXCL9 2 35.573 0.81 34.213 3.57 1.36 1.777 0.075
24 36.753 1.32 31.950 2.78 4.803 6.464 0.008
IL-1 2 31.717 1.05 30.737 3.19 0.98 2.788 0.001
24 32.655 0.95 29.012 2.05 3.643 22.11 0.001
IL-1 2 27.766 1.11 25.343 1.87 2.423 7.58 0.001
24 29.455 2.35 24.013 3.15 5.442 21.096 0.001
IL-6 2 33.47 5.70 30.77 10.9 2.5 7.913 0.001
24 37.03 1.34 33.07 6.22 3.14 17.94 0.001
EMR1 2 28.06 0.12 28.40 0.38 0.4 1.072 0.824
24 34.48 2.68 33.14 1.02 1.34 2.521 0.124
CSF1R 2 22.16 0.06 22.60 0.02 0.44 1.51 0.396
24 28.02 1.3 27.22 0.69 0.8 1.73 0.199
INFGr1 2 33.097 0.33 33.110 0.62 0.013 1.103 0.539
24 35.340 3.68 33.477 0.62 1.863 1.12 0.480
Caspase-3 2 30.91 0.63 31.25 1.17 0.34 1.089 0.724
24 30.92 1.27 30.64 1.11 0.28 1.293 0.3
-Actin 2 19.938 0.22 20.256 0.13 0.318 0.815 0.113
24 20.26 0.31 20.36 0.15 0.1 0.937 0.127
GAPDH 2 20.162 0.3 20.662 0.43 0.5 1.18 0.5
24 20.531 0.23 20.352 0.25 0.179 1.132 0.658
a Primer sequences are listed in Table S1 in the supplemental material.
b P values compare GBS-infected group with control (PBS) group within each time point per Materials and Methods.
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dehydrogenase (GAPDH) and -actin were used as reference genes.
Primer sequences for each target gene are shown in Table S1 in the sup-
plemental material. Separate reactions were carried out to ensure that the
efficiency of amplification of the reference gene was approximately equal
to that of the target gene. Relative expression levels of target genes were
determined by normalizing reaction threshold cycle (CT) values to the
housekeeper genes, GAPDH, and -actin. 	CT values were used in the
formula 2.0  (	CT) for calculation of the relative mRNA expression
levels of target genes as previously described using PCR efficiencies and
mean crossing-point deviations between samples and controls (56, 57).
Statistical analysis and bioinformatics. For data preprocessing, raw
array data were normalized using quantile normalization and summa-
rized using RMA in the affy package in Bioconductor (http://www
.bioconductor.org), as described elsewhere (13). Differentially expressed
genes were identified by analyzing data using the MAANOVA package
(http://www.bioconductor.org/packages/bioc/1.8/html/maanova.
html). To identify significant changes in expression induced by GBS, we
used a shrinkage-based t test together with permutation (9, 10). A false
discovery rate (FDR) of 0.1 was used to generate the significant-gene list.
Gene class testing was performed using the SAFE package in Bioconduc-
tor by applying thresholds to select significant pathways (4). Both the
Kyoto Encyclopedia of Genes and Genomes (KEGG) (29, 48) and Gene
Ontology (GO) (2) databases were used to generate a signaling network
from the gene class analysis. An FDR of 0.1 was used as a cutoff for both
tools. GoMinerwas used to analyze functional groups of genes activated in
biological pathways and to generateVenndiagrams of functionally related
responses. InnateDB (http://innatedb.ca) was used to provide an integra-
tive system-level analysis of functional groups activated within biological
pathways. Overrepresentation analysis (ORA) of pathways in innateDB
was performed using significant-gene lists, the hypergeometric algorithm,
and the Benjamini Hochberg correctionmethod with the pathwayORA P
value significance set at 0.05.
Microarray data accession number. The raw data sets for array com-
parisons have been deposited in the Gene Expression Omnibus database
under accession no. GSE27575 (http://www.ncbi.nlm.nih.gov/geo/).
RESULTS
Serotype III GBS colonizes the bladder uroepithelium in vitro
and in vivo. Initial binding assays using human T24 and 5637
bladder uroepithelial cells showed adherence of the serotype III
GBS isolate to these cells within 30min after infection (Fig. 1A and
B; T24 cells shown). These results are consistent with results pre-
viously reported for serotype II GBS (83). Changes in cellular ar-
chitecture were noted in some cells to which GBS had bound
(compare Fig. 1A and C). Similar results were observed in 5637
bladder cells (not shown). In the murine model, the serotype III
GBS isolate was also observed bound directly to the surface of the
bladder uroepithelium as early as 2 h following transurethral in-
fection. Colonization was observed as focal areas of adhesion
across the bladder surface, which was visualized using fluores-
cence dissection stereomicroscopy to detect FITC-GBS (Fig. 1D
and E). Resected areas of bladder processed and imaged using
high-resolution SEMconfirmed binding of serotype IIIGBS to the
uroepithelium in vivo at 2 h following challenge (Fig. 1F and G).
Histological assessment of control (Fig. 1H to J) andGBS-infected
(Fig. 1K to M) bladders using hematoxylin and eosin (H&E) and
IHC illustrated a local cellular infiltrate at 24 h comprised of poly-
morphonuclear leukocytes (PMNs), as shown by IHC (compare
controls [I and J] with GBS-infected panels [L and M]).
Dynamics of early GBS uroepithelium binding and dose re-
sponse. Initial quantitation of early binding of GBS to 5637 blad-
der uroepithelial cells after infection in vitro showed that only
0.15% of the total bacteria used for challenge bound to bladder
cells after 30 min (Fig. 2). This amount of adherence was higher
than the UPECCFT073 adherence at 30min; however, this differ-
ence was not statistically significant. A notable difference after 2 h
inwhich totalGBS adherence remained at only 0.15% (adherence/
invasion) but UPEC adherence had increased to 2.5%, which rep-
resented a statistically significant difference, was observed (Fig. 2).
Intracellular survival data at 24 h after antibiotic protection
showed that GBS was recovered from the intracellular compart-
ment of host cells in numbers comparable to that ofUPEC (Fig. 2).
Thus, GBS binds to bladder uroepithelial cells rapidly (within 30
min) and efficiently compared to UPEC in vitro, is able to invade
these cells, and is able to survive under intracellular conditions for
at least 24 h.
In escalating challenge dose assays in mice, we calculated the
ID50 and ID90 values of the GBS isolate in this study to be 1.2 and
2.9  109 CFU, respectively. We based these calculations on the
number of mice exhibiting positive bladder cultures at 24 h
postinfection (Fig. 3A).We then quantitated early GBS binding to
the bladders in mice that received an ID90 challenge dose of 3 
109 CFU, which was used in subsequent assays. In assays based on
extensive washing of bladders immediately after infection, we ob-
served efficient binding of GBS to the surface of the bladder uro-
epithelium in vivo after 30 min (Fig. 3B). The majority of GBS
present in the bladders of mice at 30 min represented bound bac-
teria, since there was no difference in total bladder load between
tissues that were unwashed (U/W) and those that were extensively
washed (W). The differences between U/W andW bladders from
mice infected with UPECCFT073, on the other hand, were signif-
icant (P 0.015; Fig. 3B). These data demonstrate at least equally
efficient binding of GBS to the bladder uroepithelium surface
compared toUPEC. The average bladderGBSburden after 2 hwas
106 CFU/0.1 g tissue, which decreased 100-fold after 24 h (Fig.
3C). These decreases in GBS load between 2 h, 24 h, and 5 days
were statistically significant (P
 0.05), demonstrating a decline in
bacterial burden over time to a point at 5 days when most mice
were bladder culture negative. A few mice exhibited positive kid-
ney cultures at 2 h, 24 h, and 5 days (Fig. 3D); however, there were
no significant differences in the mean recovery of GBS from kid-
neys between any of these time points. High numbers of GBSwere
detected in the urine at 2 h that also subsequently declined by 24 h
but then exhibited equivalent mean bacteriuria levels between 24
h and 5 days (Fig. 3E).
Some uropathogens, including E. coli, are able to utilize urine
for growth (33, 64, 89), and we next sought to determine whether
GBS might replicate in urine in the bladder to gain insight into
whether this might affect the dynamics of uroepithelium coloni-
zation. In vitro growth assays performed using GBS and fresh hu-
man urine demonstrated virtually no bacterial replication over a
time course of 72 h (Fig. 4A). Similar data were observed for
growth curves determined using fresh urine from C57BL/6 mice
(not shown). In contrast, we observed rapid growth for two con-
trol E. coli strains that were used in these assays, UPEC CFT073
and E. coli 83972 (Fig. 4A). To determine whether a general
growth defect might be present in this GBS isolate, we also per-
formed parallel growth curve assays using rich THB. However,
there was no general growth defect in the uropathogenic serotype
III GBS isolate in THB (Fig. 4B). Together, these data show that
GBS is unable to utilize urine for growth; hence, GBS growth in
urine is unlikely to influence the dynamics of uroepithelium col-
onization during infection in mice.
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FIG 1 Attachment of uropathogenic serotype III GBS to human bladder uroepithelial cells in vitro (A, 30min; B, 2 h; C, control) and colonization of the surface
of bladder uroepithelium inmurine GBSUTI as analyzed by fluorescencemicroscopy of whole tissue, illustrating focal areas of adheredGBS (D and E) alongside
images of pockets of boundGBS between folds of uroepithelium (F andG) as analyzed with high-resolution SEM.Histological assessment of control (H to J) and
GBS-infected (K to M) bladders illustrates a PMN infiltrate at 24 h (arrowheads), as demonstrated in serial sections stained using either H&E (H and K) or
PMN-specific Gr-1 antibody and IHC techniques (I and J, L and M). Bars, 50 M (small bars) and 180 M (large bars).
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GBS bladder transcriptome. Initial genome-wide expression
profiling of bladder failed to identify any genes with significantly
altered expression immediately after GBS infection at 2 h. This
finding was unexpected given the high GBS bladder burdens that
were detected at this early time point (Fig. 3C) and the overall
lower variance in total bladder-urine bacterial loads betweenmice
within the 2-h group compared to later time points. In contrast to
the array data sets at 2 h, comparison of infected and control mice
at 24 h revealed a diverse set of 172 genes with significant changes
in expression (FDR 0.1). Heat maps for arrays illustrating over-
all gene signal intensities in the samples at 24 h are shown in
Fig. 5A alongside a volcano plot illustrating the overall breadth of
the GBS bladder transcriptome at 24 h in Fig. 5B. The complete
significant-gene list at 24 h is presented in Table 2. A summary of
the gene expression changes plotted according to FDR for the top
75 genes (FDR  0.05) is shown in Fig. S1 in the supplemental
material alongside a Venn diagram derived using GoMiner for
responses related to defense against bacteria, cytokines, and in-
flammation. The raw data sets for array comparisons have been
deposited on the Gene Expression Omnibus website (see Materi-
als and Methods for accession number).
Overall, the GBS bladder transcriptome comprised genes en-
coding multiple mediators of defense, including those known to
be responsive toGBS in othermodels of infection, including IL-1
(3.7-fold change, FDR  0.035), IL-1 (10.1, 0.011), IL-6 (3.3,
0.093), Stat1 (4.5, 0.03), Stat2 (3.11, 0.04), Ccl5 (2.10, 0.044), and
multiple poly(ADP-ribose) polymerases (PARPs) (5, 20, 23, 31,
49, 58, 77, 81, 83). Other transcripts that encode ILs and their
receptors or receptor antagonists, including IL-1 familymember 9
(4.7, 0.033), IL-1r antagonist (1.8, 0.082), IL-2rg (3.4, 0.048), IL-
13ra1 (3.0, 0.088), and IL-17rd (0.7, 0.066), were also identified in
the response. Chemokine and chemokine receptor gene expres-
sion, including that of Cxcl10 (25.4, 0.006), Cxcl5 (4.27, 0.071),
Cxcl9 (3.99, 0.075), and Ccl12 (2.9, 0.078), was also prominent.
Other responses of note were related to apoptosis regulators and
effectors, including PARP family members 9 (2.8, 0.058), 12 (2.5,
0.053), and 14 (3.1, 0.088), CARD 5 (3.0, 0.035), and neutrophil
apoptosis (3.3, 0.093), given the ability of GBS to induce apoptosis
and PARP cleavage (79). Unexpectedly, several key defense mol-
ecules associated with GBS in other (non-UTI) infection models
such as inducible nitric oxide synthase (iNOS) (78) and TNF-
(27) were not detected as significantly altered in expression in the
bladder transcriptome.
qRT-PCR. qRT-PCR showed that expression levels of selected
target genes were consistent with individual gene responses iden-
tified using arrays. For example, Cxcl10, which was the most
strongly activated gene induced byGBS according to arrays at 24 h
(25.40-fold increase [P  0.006]; Table 2), was also highly ex-
pressed according to qRT-PCR (Table 1; 30.75-fold increase [P
0.001]). Similarly, multiple other genes, including those that
encode iNOS, CCL5, CXCL5, CXCL9, IL-6, IL-1, and IL-1,
were upregulated according to both qRT-PCR and arrays. As
expected, there were a number of genes that were tested by
qRT-PCR that exhibited higher fold increases compared to ar-
rays because PCR is more sensitive than the arrays (Table 1 and
data not shown). All of these transcripts were detected at sev-
eral cycles above background levels, which validates the detec-
tion of genes with low CT values (e.g., IL-6). The housekeeping
genes -actin and GAPDH also showed no significant changes
according to qRT-PCR, which was consistent with findings in
arrays. This was also consistent with findings determined for
several other genes that showed no significant changes in ex-
pression according to arrays and qRT-PCR (e.g., genes for
EMR1, CSFR1, INFGr1, and Caspase-3).
Bioinformatics analysis of biological pathways in the tran-
scriptome. Initial analysis of biological pathways within the GBS
bladder transcriptome by gene class testing using the KEGG data-
base identified no significant interactions with P values
 0.25 for
comparisons between infected and controlmice at 2 h. In contrast,
there were 34 significantly enriched KEGG pathways at 24 h (Ta-
ble 3). The most strongly represented pathways at 24 h were those
related to host responses to bacterial infection; for example, path-
ways for metabolism (KEGG pathways 561, 562, and 630), ABC
transport (2010), focal adhesion (4510), extracellular matrix re-
ceptor interactions (4512), Toll-like receptors (TLRs) (4620), NK
cell-mediated cytotoxicity (4650), and B cell receptor signaling
(4662), which were all significantly overrepresented. Others of
interest were those for mitogen-activated protein kinase (MAPK)
signaling (KEGG pathway 4010), apoptosis (4210), T cell receptor
signaling (4660), antigen processing and presentation (4612), and
cytokine-cytokine receptor interactions (4060).
Subsequent GO biological process analyses of the array data
for GBS-infected mice at 2 h and 24 h, shown in Table S2 in the
supplemental material, revealed larger numbers of overrepre-
sented pathways compared to those derived using KEGG as de-
scribed above: 40 and 278, at 2 h and 24 h (P
 0.05), respectively.
Interestingly, several pathways identified at 2 h using GO indi-
cated that GBSmight suppress early host responses in the bladder
following infection. These pathways related to downregulation
of the defense response (pathway 0031348), downregulation of
the response to stimulus (0048585), and downregulation of the
inflammatory response (0050728) (see Table S2 in the supple-
mental material). Pathways related to immune activation and
upregulation of antimicrobial defense were highlighted at 2 h
but were more prominent at 24 h. These included pathways for
T-lymphocyte-mediated immunity (0002456), nitric oxide synthesis
(0006809), TNF- production (0032640), and upregulation of the
innate immune response (0045089). Concomitant activation of im-
mune-suppressive pathways for adaptive responses (0002820) and
cytokine synthesis (0042036) was also identified at 24 h, illustrating a
balance of pro- and anti-inflammatory responses.
FIG2 Quantitation of adherence and intracellular survival of serotype III GBS
in human bladder uroepithelial cells in vitro. The percentage of bacteria bound
to 5637 cells after 30 min (representing initial adherence) is shown for GBS,
alongside the percentage bound and invaded at 2 h and the percentage of
intracellular bacteria recovered from bladder cells after 24 h after antibiotic
protection. The equivalent data for UPEC CFT073 are shown for comparison.
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Integrated system-level analysis.We next used the InnateDB
database as a complementary bioinformatics tool to enable inte-
grative system-level analyses of the array data. This identified 293
distinct biological pathways at 24 h, which included an additional
15 pathways compared to those that were identified using GO.
Mining of the data within InnateDB by ORA identified 168 over-
represented pathways at 24 h (P 
 0.05; see Table S2 in the sup-
plementalmaterial). Themost significant of these with the highest
number of activated genes were those for cytokine receptor inter-
actions (pathway 604) and chemokine signaling (4351), shown in
Fig. 6.Many of the interactors in the pathways that were identified
exhibited a large number of interactions such as TRAF6 (525 in-
teractors), although others, such as TNF (39 interactors) and
TLR-9 (16 interactors), exhibited fewer interactors.
Common and GBS-unique elements of the bladder tran-
scriptome. Direct comparisons of gene expression responses in
bladders of mice challenged with GBS and UPEC enabled us to
ascertain the degree of response conservation in the bladder tran-
scriptome. These comparisons used bladders from GBS-infected,
UPEC-infected, and PBS control mice in a single experiment per-
FIG 3 Infectious dose and temporal colonization dynamics of uropathogenic serotype III GBS in a murine model of UTI. Data for escalating dose assays
(A) and measures of early bladder adherence of GBS in mice challenged with the ID90 after 30 min (B) are shown alongside persistence data for GBS in the
bladder (C) and kidneys (D) and bacteriuria levels (E). Broken lines indicate the detection limit for each sample type based on the volume plated. Initial
binding of GBS to bladder uroepithelium as represented in panel B was determined by comparing unwashed (U/W) bladders (bound GBS plus those
present in bladder lumen) (n 6) with washed (W) bladders (representing only adherent bacteria after 30 min), and the results are shown alongside data
for UPEC for comparison. Temporal colonization data (C, D, and E) represent pooled data from mice challenged with the ID90 in two separate
experiments with at least 9 mice per group per experiment. Statistical comparisons between groups are based on Mann-Whitney U tests with P values set
for significance at 0.05.
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formed with the one control group to map global gene expression
responses. An absence of significant changes in gene expression
induced by GBS in the bladder at 2 h according to array analysis
contrasted strikingly with data obtained from mice infected with
UPEC for 2 h. These data, which were recently published (13),
showed that mice develop a 2-h bladder transcriptome of UPEC
UTI that comprises 1,564 transcripts with significant fold differ-
ences compared to controls. Microarray analysis at 24 h in the
current study showed that, in contrast to the 172 significant
changes in gene expression triggered by GBS (Table 2), UPEC
induced 15-fold-more significant changes in gene expression at
this time point. The 24-h bladder transcriptome of UPEC UTI in
C57BL/6 mice revealed a significant-gene list of 2,507 genes
(FDR  0.05), which is shown in Table S3 in the supplemental
material. Raw array data forUPEC-infectedmice at 24 h have been
deposited in the Gene Expression Omnibus database (see Materi-
als and Methods for accession number), and data defining bacte-
rial loads in these mice, along with 2-h array data sets, are de-
scribed elsewhere (13).
An overall comparison of the bladder transcriptomes triggered
by GBS and UPEC UTI at 2 h and 24 h is illustrated by volcano
plots in Fig. 7. These plots highlight the total number of shared
gene expression responses that we identified as commonly in-
duced/repressed by both pathogens at 24 h (black stars in panels B
to D; FDR
 0.05) and also illustrate the much larger number of
microbe-specific gene expression patterns that were induced in
the bladder at 24 h (red diamonds in panels A to C; FDR
 0.05).
In total, the common bladder gene expression responses that were
induced/repressed by both GBS and UPEC models at 24 h com-
prised only 68 genes, which are listed in detail in Table S4 in the
supplemental material. The plots in Fig. 7 also illustrate the nota-
bly slower innate bladder response to GBS (Fig. 7A and B) com-
pared to the more rapid and broader response induced by UPEC
(Fig. 7C and D).
FIG 4 In vitro growth curve assays of uropathogenic serotype III GBS in pooled human urine (A) and in THB (B) as measured at OD600. The equivalent growth
curve data derived from control E. coli strains UPEC CFT073 and 83972 in parallel assays are shown for comparison.
FIG 5 Global gene expression in bladder during GBS cystitis in mice comprises a significant list of 172 genes (FDR 
 0.1) derived from comparisons of
infected and control (Ctrl) mice at 24 h (n  5). Gene signal intensities are illustrated in the heat maps for individual arrays (A). The complete
significant-gene list is provided in Table 2. The summary response is shown using a volcano scatterplot (B) where significant genes are displayed as
shrinkage t test results [log10(P value)] (y axis) versus expression ratio [log2(mean GBS infected/control)] (x axis), with vertical lines representing a
2-fold difference; red diamonds represent FDR 
 0.1.
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TABLE 2 Global gene expression in bladder during GBS cystitis in mice
comprises a significant-gene list of 172 genes (FDR
 0.1) derived from
pairwise comparisons of infected mice with control mice (n 5) at 24 h
postinfection
Gene assignment Target gene product Fold change FDRa
NM_021274 Cxcl10 25.4 0.006
NM_008324 Indo 14.87 0.006
NM_011579 Tgtp 10.94 0.019
NM_021792 Iigp1 10.55 0.015
NM_008361 Il1b 10.12 0.011
NM_011410 Slfn4 9.42 0.015
BC034256 Tgtp 8.75 0.011
NM_011260 Reg3g 8.7 0.075
XM_905096 Irgb10 7.92 0.015
L38281 Irg1 7.03 0.011
NM_008620 Gbp4 6.89 0.022
NM_008331 Ifit1 6.81 0.031
NM_008326 Irgm 6.54 0.015
BC112328 LOC626578 6.51 0.022
NM_011315 Saa3 6.44 0.046
NM_009114 S100a9 6.38 0.035
NM_018738 Igtp 6.35 0.018
NM_144559 Fcgr4 5.94 0.053
NM_011407 Slfn1 5.83 0.026
NM_010999 Olfr56 5.75 0.025
NM_020498 Ly6i 5.71 0.035
NM_153564 Gbp5 5.48 0.022
NM_177162 9930032O22Rik 5.43 0.047
NM_010260 Gbp2 5.42 0.022
NM_029499 Ms4a4c 5.41 0.079
ENSMUST031549 EG240327 5.3 0.051
NM_021394 Zbp1 5.04 0.051
NM_011346 Sell 4.96 0.044
NM_010927 Nos2 4.74 0.015
NM_153511 Il1f9 4.7 0.033
NM_133871 Ifi44 4.65 0.044
NM_009099 Trim30 4.62 0.035
NM_009283 Stat1 4.5 0.03
NM_172777 BC057170 4.45 0.046
NM_010501 Ifit3 4.33 0.035
NM_009141 Cxcl5 4.27 0.071
NM_023137 Ubd 4.22 0.035
NM_011472 Sprr2f 4.09 0.057
NM_021384 Rsad2 4.07 0.044
NM_018734 Gbp3 4.05 0.048
NM_145545 Gbp6 4.03 0.047
NM_016850 Irf7 4.02 0.056
NM_010819 Clec4d 4 0.077
NM_008599 Cxcl9 3.99 0.075
NM_020557 Tyki 3.96 0.025
NM_008230 Hdc 3.91 0.068
NM_008462 Klra2 3.87 0.068
NM_013532 Lilrb4 3.87 0.083
NM_008329 Ifi204 3.83 0.068
NM_011854 Oasl2 3.78 0.035
NM_010554 Il1a 3.72 0.035
NM_023386 Rtp4 3.7 0.041
NM_145226 Oas3 3.57 0.022
AB112025 Sirpb1 3.52 0.088
NM_021893 Cd274 3.49 0.015
NM_028595 Ms4a6c 3.43 0.078
XR_033405 LOC546714 3.43 0.094
NM_025777 Duoxa2 3.41 0.046
NM_023044 Slc15a3 3.38 0.047
TABLE 2 (Continued)
Gene assignment Target gene product Fold change FDRa
NM_008390 Irf1 3.37 0.047
NM_013563 Il2rg 3.35 0.048
NM_008491 Lcn2 3.34 0.079
NM_031168 Il6 3.31 0.094
NM_008332 Ifit2 3.3 0.051
EF660528 AW112010 3.27 0.046
NM_029509 5830443L24Rik 3.26 0.068
NM_009251 Serpina3g 3.19 0.069
NM_011157 Srgn 3.15 0.053
NM_001040005 Rnf213 3.15 0.077
NM_145227 Oas2 3.13 0.058
NM_019963 Stat2 3.11 0.035
NM_001039530 Parp14 3.07 0.088
NM_139198 Plac8 3.06 0.094
NM_011347 Selp 3.05 0.075
NM_133990 Il13ra1 3.04 0.088
NM_183201 Slfn5 3.03 0.091
NR_003508 Mx2 3.01 0.081
AK220210 Nlrc5 2.98 0.035
NM_018851 Samhd1 2.96 0.057
NM_011408 Slfn2 2.93 0.069
NM_013683 Tap1 2.87 0.075
NM_011909 Usp18 2.86 0.046
NM_011331 Ccl12 2.86 0.078
ENSMUST051264 Cd300lf 2.85 0.082
NM_008848 Pira6 2.84 0.078
NM_030253 Parp9 2.83 0.058
NM_001013371 Dtx3l 2.8 0.046
NM_027835 Ifih1 2.8 0.09
NM_001038604 Clec5a 2.78 0.083
NM_001033308 BC013712 2.74 0.066
NM_010259 Gbp1 2.67 0.029
NM_011852 Oas1g 2.65 0.079
NM_010553 Il18rap 2.59 0.066
NM_029084 Slamf8 2.58 0.044
NM_172893 Parp12 2.51 0.053
NM_181754 Gpr141 2.5 0.049
NM_013673 Sp100 2.48 0.09
ENSMUST047498 AA467197 2.47 0.043
NM_145209 Oasl1 2.38 0.098
NM_008152 Gpr65 2.32 0.083
NM_008348 Il10ra 2.29 0.078
NM_010747 Lyn 2.26 0.046
NM_172689 Ddx58 2.22 0.061
NM_001024134 Trim15 2.22 0.069
NM_145133 T2bp 2.19 0.075
NM_009890 Ch25h 2.19 0.078
NM_019401 Nmi 2.17 0.078
BC117807 Ibrdc3 2.1 0.035
NM_013653 Ccl5 2.1 0.044
NM_026913 Mitd1 2.1 0.056
NM_001013817 Sp140 2.02 0.07
NM_009277 Trim21 1.99 0.078
NM_008217 Has3 1.88 0.083
NM_030701 Gpr109a 1.84 0.089
AK034303 9330175E14Rik 1.82 0.044
NM_145391 Tapbpl 1.82 0.078
NM_031167 Il1rn 1.82 0.082
NM_207648 H2-Q6 1.8 0.056
NM_030720 Gpr84 1.73 0.092
NM_001001495 Tnip3 1.73 0.099
NM_011530 Tap2 1.71 0.075
(Continued on following page)
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Bladder uroepithelial cells provide innate defense against
GBS. We next undertook an analysis of GBS-infected human
bladder 5637 uroepithelial cells in vitro to assess whether uroepi-
thelial cells might contribute to the responses that we observed in
the bladder transcriptome in mice. For this, we used a multiplex
bead-based analysis of cell culture supernatants and compared the
response of infected cells to that of control (noninfected) cells for
a panel of 8 protein targets that were selected on the basis of sig-
nificant gene expression responses in the bladder transcriptome
and cellular infiltrate data. These experiments were performed in
parallel with UPEC experiments for direct comparisons. The re-
sults, shown in Fig. 8, illustrate that uroepithelial cells contribute
to host defense against GBS through the production of several
cytokines, including IL-1 and IL-1ra. Several of these responses
were consistent with gene expression patterns observed in mice.
Increased production of the chemokine IL-8 by uroepithelial cells
at 24 h in response to GBS (Fig. 8) also correlated with the PMN
infiltrate observed in the bladder ofmice at 24 h (Fig. 1). Compar-
ing the overall responses induced by GBS with those triggered by
UPEC showed that several but not all target proteins were induced
more strongly by UPEC. These included IL-8 and granulocyte-
macrophage colony-stimulating factor (GM-CSF) but not IL-1
or IL-1ra. Other target proteins, including IL-6, IL-13, IL-17, and
CCL5, were not significantly induced by GBS over the time course
assessed in the human cell culture model, even though these or
closely related factors (e.g., IL-13ra1, IL-17rd) were significantly
induced/repressed in the GBS bladder transcriptome. Thus, uro-
epithelial cells contribute to defense against GBS, and several (but
not all) responses of human bladder cells are consistent with tran-
scriptional responses in the murine GBS bladder transcriptome.
TABLE 2 (Continued)
Gene assignment Target gene product Fold change FDRa
NM_183162 BC006779 1.71 0.078
NM_145373 Sectm1a 1.66 0.058
NM_175397 Sp110 1.59 0.099
NM_001033339 Mmp25 1.5 0.068
NM_024495 Car13 1.43 0.098
NM_010380 H2-D1 1.35 0.083
NM_198013 Cuedc1 0.79 0.1
NM_001085492 Rere 0.78 0.083
NM_181039 Lphn1 0.77 0.058
NM_173186 Tbc1d24 0.76 0.082
NM_172619 Adamts10 0.74 0.04
NM_007405 Adcy6 0.74 0.046
NM_173788 Npr2 0.74 0.046
NM_198300 Cpeb3 0.74 0.079
NM_032418 Dmpk 0.74 0.091
NM_177030 Dock6 0.73 0.035
NM_029967 Adamtsl1 0.72 0.025
NM_011242 Rasgrp2 0.72 0.083
NM_053097 Cml3 0.72 0.083
NM_011066 Per2 0.71 0.071
XM_990451 AU042671 0.71 0.088
NM_173749 E430002G05Rik 0.71 0.092
NM_134437 Il17rd 0.7 0.066
NM_001042779 Sema3b 0.7 0.088
NM_011218 Ptprs 0.69 0.051
BC057903 Col6a3 0.69 0.064
NM_022814 Svep1 0.69 0.081
NM_007496 Zfhx3 0.68 0.035
NM_175473 Fras1 0.67 0.1
NM_177030 Dock6 0.66 0.058
NM_008483 Lamb2 0.66 0.083
NM_053185 Col4a6 0.65 0.015
NM_031176 Tnxb 0.65 0.078
NM_027890 Susd2 0.64 0.05
NM_001033323 Igsf9b 0.64 0.071
NM_007463 Speg 0.64 0.078
NM_001012765 Adcy5 0.63 0.056
NM_001033476 Ahnak2 0.62 0.029
NM_013630 Pkd1 0.62 0.046
NM_012040 Pnck 0.62 0.088
NM_010570 Irs1 0.6 0.027
NM_013568 Kcna6 0.6 0.09
NM_175750 Plxna4 0.59 0.015
NM_139001 Cspg4 0.58 0.09
NM_008742 Ntf3 0.57 0.071
XR_034431 LOC100048255 0.56 0.058
XR_034431 LOC100048255 0.55 0.035
NM_052835 Rpl10 0.55 0.084
NM_009154 Sema5a 0.54 0.014
NM_009204 Slc2a4 0.54 0.035
NM_176922 Itga11 0.54 0.083
a FDR, false discovery rate.
TABLE 3 Activation of diverse KEGG regulatory networks in bladder
during GBS cystitis
KEGG no. Pathway P
00561 Glycerolipid metabolism 0.01
00562 Inositol phosphate metabolism 0.01
00630 Glyoxylate and dicarboxylate metabolism 0.01
02010 ABC transporters 0.01
04510 Focal cell matrix adhesion 0.01
04512 Extracellular matrix-receptor interaction 0.01
04620 Toll-like receptor signaling 0.01
04650 Natural killer cell-mediated cytotoxicity 0.01
04662 B cell receptor signaling 0.01
04810 Regulation of actin cytoskeleton 0.01
04920 Adipocytokine signaling 0.01
04010 MAPK signaling 0.014
04930 Type II diabetes mellitus 0.014
05060 Unknown 0.017
00620 Pyruvate metabolism 0.018
03320 Peroxisome proliferator-activated receptors 0.018
04210 Apoptosis 0.02
00970 Aminoacyl-tRNA biosynthesis 0.023
04670 Leukocyte transendothelial migration 0.023
05020 Unknown 0.023
03450 Nonhomologous end joining 0.028
00480 Glutathione metabolism 0.03
00220 Urea cycle and metabolism of amino groups 0.033
00980 Metabolism of xenobiotics by cytochrome P450 0.033
00982 Drug metabolism—cytochrome P450 0.033
05222 Small cell lung cancer 0.033
04060 Cytokine-cytokine receptor interaction 0.035
04742 Taste transduction 0.035
04612 Antigen processing and presentation 0.036
04630 Jak-STAT signaling 0.039
04660 T cell receptor signaling 0.04
04912 Gonadotropin-releasing hormone signaling 0.04
00790 Folate biosynthesis 0.042
04664 Fc epsilon RI signaling 0.048
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DISCUSSION
Cystitis due to bacterial infection stems frommicrobial adherence
to uroepithelial cells, which facilitates resistance to the natural
hydrodynamic forces of urine flow that remove potential patho-
gens from the bladder. Uropathogenic GBS was shown to adhere
to uroepithelial cellsmore efficiently than nonuropathogenic GBS
in a prior study (83), and the organisms’ hemolysin-cytolysin was
shown to contribute to the pathogenesis of UTI in mice (35).
However, the early events in bladder colonization and the mech-
anisms of host defense activated immediately following infection
with GBS are largely unknown. The results of the current study
show that GBS is able to bind to mouse and human bladder uro-
epithelium rapidly, within minutes of infection, and relatively ef-
ficiently compared to the best-adapted bacterial uropathogen,
UPEC. This study also shows for the first time that GBS is able to
invade human bladder uroepithelial cells and is able to survive
inside these cells for at least 24 h, which may contribute to UTI
pathogenesis. Adherence to and invasion of bladder uroepithe-
lium set the stage for progression to cystitis once the bacteria are
detected by innate immune surveillance mechanisms.
Innate immune signaling cascades are initiated within hours of
contact with bacterial pathogens in various infectious settings (17,
18, 71, 95, 96) and are induced in themurine bladder within 2 h of
UPEC UTI (13). Such rapid inflammatory responses in the blad-
der in response to UPEC are exemplified by a 1,000-fold increase
in TNF- expression at 1 h postinfection, which precedes high
bladder bacterial loads at 1 day (28), and induction of CXCL1,
CXCL6, and MIP-2 within 4 h (7, 25). Surprisingly, despite sub-
stantial GBS bladder burdens early in the course of UTI in this
study, GBS failed to trigger robust inflammation within 2 h of
infection in mice according to genome-wide transcriptomic anal-
ysis. Thus, GBS UTI contrasts with UPECUTI in terms of presen-
tation of the higher GBS bladder burdens very early during infec-
tion which precede the bulk of inflammatory responses that occur
FIG 6 Immune activation in the GBS UTI transcriptome comprises prominent cytokine-cytokine receptor signaling (innateDB pathway number 604) (A)
in which 12 genes were highly active (red circles; expression and significance cutoffs, 2.0 and 0.1). The pathway is illustrated according to subcellular
localization and includes the total of 255 genes annotated in the pathway. The bladder transcriptome also includes chemokine signaling (innateDB
pathway 4351) (B), with activation of the pathway occurring via 8 genes (red circles; Cxcl10, Cxcl9, and Stat2 are shown twice) among a total of 175 genes
in the pathway.
FIG 7 Pathogen-specific defense against GBS in the bladder involves fewer
gene expression responses, and these are slower to develop than responses
elicited by UPEC. Volcano scatterplots (A and B) illustrate significant genes
identified by shrinkage t test results at 2 h and 24 h for GBS, compared to those
for UPEC (C and D). Red diamonds represent genes at FDR 
 0.05 for both
pathogens. Significant changes in gene expression for those genes identified as
common (i.e., induced/repressed by both GBS and UPEC after 24 h) are de-
noted by black stars in panels B and D and are listed in detail in Table S4 in the
supplemental material. These common responses illustrate the exact combi-
nation of shared and pathogen-specific responses in the bladder transcrip-
tomes due to these two organisms.
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at 24 h postinfection. Our data also indicate that GBS bladder
burdens are not influenced by the presence of urine because the
bacteria could not utilize this for growth in vitro, in contrast to
UPEC. High GBS loads observed at 2 h in this study are consistent
with recent findings of high bladder bacterial loads in C3H/HeN
mice at 3 h (35) that progressed with relatively mild immune re-
sponses in the bladder. Taken together, these findings suggest that
the dynamics of early GBS bladder colonization in these two
strains of mice are similar.
This study also showed that innate bladder responses to GBS
unfold slowly compared to responses to UPEC and that the
breadth of the responses to GBS is more limited in scope. The
nature of the pathogen-specific response during cystitis in mice
due to these two organisms was unmistakable because of the com-
parative analyses that were undertaken in parallel across the entire
genome.We chose to administer the same infectious dose for both
organisms in terms of cell number for our array experimental
design in order to precisely control this comparison. However, it
would also be interesting to compare gene expression responses in
mice given lower doses of UPEC, which, based on prior observa-
tions, would be closer to the ID90 for this pathogen. Our compar-
isons identified only 68 shared gene expression responses induced
by bothGBS andUPEC, which illustrates that themajority of gene
expression changes in the bladder triggered by these organisms are
pathogen specific. The bioinformatics findings in this study are of
particular interest, because they reveal a marked induction of in-
nate defense mechanisms against GBS in UTI that are essentially
unknown in host responses to GBS in general. Some of these, such
as ABC transporters, have prominent roles in infectious disease
pathogenesis in other settings, and these would be of interest in
future GBS host-pathogen studies. Other biological pathways
identified by KEGG as enriched in the GBS bladder transcriptome
such as TLRs are well-established elements of defense against GBS
in non-UTI models both in vitro and in vivo.
A relatively slower and milder innate immune response trig-
gered by GBS compared to UPEC could influence the survival of
GBS in the bladder immediately after colonization of the uroepi-
thelium. Interestingly, human blood cultures exposed to GBS also
exhibit a delayed pattern of induction of proinflammatory cyto-
kines, including IL-1 and IL-6, which are not produced until 24
FIG 8 Bladder uroepithelial cells contribute to defense against GBS through production of chemokines and cytokines. Human 5637 uroepithelial cells were
infectedwithGBS at anMOIof 10 as described inMaterials andMethods, and culture supernatants at 0.5 h, 2 h, and 24 hwere used tomeasure a panel of 8 protein
targets identified from array data and histopathology as part of the bladder response to GBS. Data derived frommultiplex protein assay are shown for each target
and represent the means standard errors of the means of the results determined for quadruplicate samples versus control (noninfected) bladder cells.
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h (86, 87). Comparisons of bladder responses to GBS with non-
UTI models reveal other commonalities in the transcriptome re-
ported here: IL-6 inGBS sepsis (5, 20, 49), for example, andCCL5,
Stat1, Parp9, IL-1, and Nos2 (23, 31, 58, 77, 81, 83). Factors that
might contribute to tissue damage in the bladder during GBS cys-
titis, includingmultiple CXC chemokines such as CXCL10 (36) as
well as IL-1 (11) and Nos2 (45), were also shown to be induced.
However, it should be noted that these factors mediate antimicro-
bial defense in some infections and thus may be important for
disease control in GBS UTI. CXCL10 and Nos2, for example, aid
in controlling Gram-negative uropathogens in the bladder (53).
The functional contribution of many of these factors in the GBS
bladder transcriptome to the progression of UTI can now be in-
vestigated based on their expression kinetics as shown in this
study.
In terms of UTI pathogenesis in general, different microbes
have been strongly linked to host features relevant to disease (76),
which underscores the importance of host factors in both control-
ling and contributing to disease. Several studies have described
pathogen-specific immune responses in the urinary tract, and
these offer valuable insight into the results of the current study. In
a recent study on upper UPEC UTI, a new TLR-4/interferon reg-
ulatory factor 3 (IRF3)-dependent pathway of pathogen discrim-
ination was defined (21). Pathogen-specific responses to UPEC
were previously associated withmucosal TLR responses involving
TLR-4-dependent, lipopolysaccharide (LPS)/CD14-independent
defense (22, 26), as reviewed elsewhere (60). In the newly de-
scribed model, commensal E. coli selectively engaged receptors
that drive IRF3 activation by UPEC, leading to epithelial gene
transcription in a pathogen-specific manner (21). In the current
study, GBS did not trigger IRF3; however, IRF1 and IRF7 were
activated transcriptionally. This implies that mechanisms involv-
ing IRF1 and IRF7, which are involved in prominent signaling
events in the GBS bladder transcriptome such as that associated
with CXCL10 (88, 94), may drive immune engagement in the
bladder early during GBS UTI. Thus, further studies would be of
interest to address the potential role of interferon regulatory fac-
tors in GBS UTI.
TLR signaling genes were identified as overrepresented in sev-
eral biological pathways in theGBSbladder transcriptome accord-
ing to innateDB, which was used to gain insight into networks
relevant to innate immunity beyond KEGG and GO (39, 40).
While there remains a debate concerning howGBS initiates innate
immune responses, there is a consensus with respect to an impor-
tant role for TLR-2. In systemicGBS infection, TLR-2 deficiency is
associated with impaired host resistance (59); in peritoneal mac-
rophages, GBS induces TLR-2-dependent gene activation (12),
and in a neonatal infection model, TLR-2 was necessary for GBS
clearance (42). There is little published data on TLR-2 signaling in
the bladder; however, a body of recent evidence suggests that
TLR-4 is central to the induction of local innate immunity (60, 72,
73, 93). TLR-4 and CXCR1 deficiency predisposes to asymptom-
atic carriage ofE. coli andpossibly other uropathogens (60). In this
study, GBS upregulated the genes for TLR-2, -11, -1, and -6 mar-
ginally but none of these responses were statistically significant.
InnateDB identified interactions involving TLR-9, suggesting rec-
ognition of unmethylated CpG GBS DNA. Upregulation of many
IL-1 family members in the GBS bladder transcriptome also sug-
gests potential involvement of TLR-2, especially considering re-
cent reports on the upregulation of IL-1 through TLR-2 in re-
sponse to intracellular infection (37) and Borrelia (6). It is also
valuable to interpret these data forGBS against those described for
enterococci in mice, which revealed TLR-2-independent inflam-
mation during pyelonephritis (30). In GBS UTI, upregulation of
TLR-2might occur later during infection (after 24 h) ormay act in
signal transduction in the absence of upregulation. However, an
absence of significant upregulation of TLR-2 early during UTI
may also explain the relatively slow bladder immune response to
GBS and the high incidence of GBSABU that is observed clinically
(84).
In this study, we observed a number of important correlations
between the GBS bladder transcriptome in mice and protein pro-
duction in human bladder uroepithelial cells that were challenged
with GBS in vitro. This is the first report, to our knowledge, that
human bladder cells contribute to defense against GBS through
the production of cytokines and chemokines, including IL-1,
IL-1ra, and IL-8. Some of these findings, such as that for IL-8,
support our histopathology observations of a notable PMN in-
flammatory infiltrate in the bladder of mice after 1 day of GBS
UTI. Other findings in the human bladder cell culture model,
however, such as an absence of response for CCL5, and other
factors related to genes identified as significant in the bladder tran-
scriptome (e.g., IL-13 and IL-17), suggest limitations of this in
vitromodel. Here, it is important to underscore the limitations of
epithelial cell monoculture models for the host response studies;
cell-cell interactions, for example, are often necessary to generate
effective antibacterial responses, as reviewed elsewhere (14). The
timing and duration of infection in suchmodels can also influence
bacterial adherence to (and invasion of) host cells, as demon-
strated in the present work for UPEC (0.5 h versus 2 h), and this
could alter cytokine responses. In these assays, we tested culture
supernatants at 0.5 h, 2 h, and 24 h, but it is plausible that these
responses could differ depending on the timing of infection.
Moreover, many cell types that would be present in the infected
bladder in vivo such as resident macrophages, lymphocytes, and
PMNs as well as other infiltrating cells were excluded from the
human cell culture model. Thus, the contribution of these cells to
defense, and the role of cytokines produced by human bladder
cells in UTI, requires further investigation. Importantly, however,
several pathogen (e.g., IL-1, IL-1ra)-specific responses were also
evident in the human bladder cell response, which supports the
finding of distinct bladder transcriptomes for GBS and UPEC ob-
served in mice. Finally, one must consider species differences be-
tween mouse and human when extrapolating protein expression
data from human bladder cells in culture to data derived from
mouse infection assays. The lack of IL-1 protein detected at 24 h
in the human cell culture model in this study, for example, con-
trasts with high levels of this cytokine induced by both GBS and
UPEC in mice at 18 to 24 h during cystitis (83). However, these
distinctionsmay reflect any of themultiple limitations inherent in
these models as described, and such comparisons are therefore
valid only in view of these various limitations.
Several recent studies on immune responses to bacterial uro-
pathogens have investigated these responses in relation to the de-
gree of immune activation in the urinary tract and the control of
disease. In Ureaplasma parvum UTI, for example, complications
of infection were shown to depend on host factors related to ex-
aggerated, as opposed tominimal, immune responses (62). In that
study, animals that developed asymptomatic, rather than acute,
UTI exhibited divergent non-PMN-related responses in the uri-
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nary tract. More minimalistic immune responses led to a higher
rate of pyelonephritis in infected animals. These findings support
the notion that the degree of host response contributes to the
pathogenesis of bacterial UTI, as discussed elsewhere (74). In the
current study, only a few mice exhibited positive kidney culture
results following challenge with GBS despite all mice harboring
high GBS bladder burdens at 2 h and most exhibiting moderate
bladder and urine burdens at 24 h. This suggests that that the early
immune responses activated by GBS in the bladder are mostly
effective in preventing ascension of the bacteria to the kidneys.
Note, however, that GBS kidney colonization patterns may differ
between mouse strains and that pyelonephritis is more prevalent
in C3H/HeN mice, which exhibit inflammation and a cellular in-
filtrate (35). These data imply that array mapping of GBS pyelo-
nephritis in mice would be useful to define immune activation
under this condition; this would ideally be undertaken using a
more consistent model of upper UTI than that described in the
current work.
Finally, our data support the observations of a recent study that
showed that GBS simultaneously stimulates and suppresses im-
mune activation, through distinct pro- and anti-inflammatory
mechanisms in the bladder (35). Our bioinformatics findings
based on GO showed that GBS activates biological pathways re-
lated to downregulation of defense and to downregulation of in-
flammation early during infection. However, GBS also triggered
pathways of T-lymphocyte-mediated immunity, nitric oxide syn-
thesis, and TNF- production. Collectively, these results confirm
that GBS simultaneously suppresses and activates bladder inflam-
mation.
In summary, this report defines a minimalistic, pathogen-spe-
cific bladder transcriptome of GBS cystitis. Many of the factors
identified within this response require future investigation to de-
fine their potential roles in defense against GBS UTI. Overall, this
report offers a critical new perspective on the uniqueness of blad-
der responses to different uropathogens and, more broadly, high-
lights the distinct mechanisms of UTI pathogenesis induced by
different bacteria.
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